CO6592086A2 - Metodo para producir proteinas de interferon recombiantes solubles sin desnaturalizacion - Google Patents

Metodo para producir proteinas de interferon recombiantes solubles sin desnaturalizacion

Info

Publication number
CO6592086A2
CO6592086A2 CO12146129A CO12146129A CO6592086A2 CO 6592086 A2 CO6592086 A2 CO 6592086A2 CO 12146129 A CO12146129 A CO 12146129A CO 12146129 A CO12146129 A CO 12146129A CO 6592086 A2 CO6592086 A2 CO 6592086A2
Authority
CO
Colombia
Prior art keywords
soluble recombinant
relates
denaturation
need
recombinant interferon
Prior art date
Application number
CO12146129A
Other languages
English (en)
Inventor
Jeffrey Allen
Ping-Hua Feng
Anant Patkar
Keith L Haney
Lawrence Chew
Lei Lei Phokham Sengchanthalangsy
Original Assignee
Pfenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfenex Inc filed Critical Pfenex Inc
Publication of CO6592086A2 publication Critical patent/CO6592086A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se relaciona con la expresión de interferón en P. fluorescens y el desarrollo de un nuevo método para extraer proteínas activas a partir del producto de fermentación utilizando detergentes suaves y sin la necesidad de un proceso de replegado.Características de la Invención: La presente invención se relaciona con el campo de la producción de proteína recombinante en anfitriones bacterianos. Adicionalmente se relaciona con la extracción de la proteína recombinante activa, soluble de una fracción insoluble sin el uso de desnaturalización y sin la necesidad de una etapa de replegado. En particular, la presente invención se relaciona con un proceso de producción para obtener altos niveles de la proteína de interferón Tipo 1 recombinante soluble de un anfitrión bacteriano.Campo de Aplicación: Método para producir rápida y económicamente altos niveles de interferón-í3 recombinante soluble en células anfitrionas de mamífero o bacterianas, sin la necesidad de etapas de desnaturalización y replegado.”
CO12146129A 2010-03-04 2012-08-28 Metodo para producir proteinas de interferon recombiantes solubles sin desnaturalizacion CO6592086A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31067110P 2010-03-04 2010-03-04

Publications (1)

Publication Number Publication Date
CO6592086A2 true CO6592086A2 (es) 2013-01-02

Family

ID=44531690

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12146129A CO6592086A2 (es) 2010-03-04 2012-08-28 Metodo para producir proteinas de interferon recombiantes solubles sin desnaturalizacion

Country Status (16)

Country Link
US (2) US9187543B2 (es)
EP (1) EP2542574B1 (es)
JP (1) JP5840148B2 (es)
KR (1) KR101857825B1 (es)
CN (1) CN102906108B (es)
AU (1) AU2011223627B2 (es)
BR (1) BR112012022292A2 (es)
CA (1) CA2791361C (es)
CL (1) CL2012002378A1 (es)
CO (1) CO6592086A2 (es)
ES (1) ES2639398T3 (es)
MX (1) MX2012010148A (es)
NZ (1) NZ602255A (es)
PE (1) PE20130557A1 (es)
RU (1) RU2573909C2 (es)
WO (1) WO2011109556A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109556A2 (en) 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CN106967175A (zh) * 2013-05-15 2017-07-21 复旦大学 长效干扰素及其制备方法和用途
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
CN107099569B (zh) * 2017-06-30 2021-05-07 北京生物制品研究所有限责任公司 一种规模化发酵生产重组人干扰素β1b蛋白的方法
CN116120424A (zh) * 2022-06-06 2023-05-16 江苏靶标生物医药研究所有限公司 一种干扰素α2b可溶性重组表达和分离纯化方法及其应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551433A (en) * 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US5702699A (en) * 1982-09-23 1997-12-30 Cetus Corporation Process for the recovery of lipophilic proteins
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4755465A (en) * 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US5281532A (en) * 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4695462A (en) * 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
US4695455A (en) * 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
GB8517071D0 (en) 1985-07-05 1985-08-14 Hoffmann La Roche Gram-positive expression control sequence
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
JP2618618B2 (ja) 1988-03-04 1997-06-11 協和醗酵工業株式会社 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5128130A (en) * 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
US5055294A (en) * 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5169760A (en) * 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
WO1992006116A1 (en) 1990-09-28 1992-04-16 Ortho Pharmaceutical Corporation Hybrid growth factors
US5508192A (en) * 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5240834A (en) * 1991-01-22 1993-08-31 Albert Einstein College Of Medicine Of Yeshiva University Solubilization of protein after bacterial expression using sarkosyl
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US6171824B1 (en) 1991-08-30 2001-01-09 Fred Hutchinson Cancer Research Center Hybrid cytokines
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
ITFI940106A1 (it) 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
RU2098124C1 (ru) * 1994-10-24 1997-12-10 Общество с ограниченной ответственностью "Ниготек" Способ получения интерферона
US5814485A (en) 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
IT1285405B1 (it) 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
JP2001523480A (ja) * 1997-11-20 2001-11-27 バイカル インコーポレイテッド サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
AU751823B2 (en) 1998-05-14 2002-08-29 Merck Patent Gmbh Fused protein
US20030167531A1 (en) * 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
AU765801B2 (en) 1999-02-18 2003-10-02 Rmf Dictagene S.A. Malaria vaccine
US7001892B1 (en) * 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
KR100358948B1 (ko) 2000-03-31 2002-10-31 한국과학기술원 인체 과립성 백혈구의 콜로니 자극인자를 분비하는 대장균
AU9096001A (en) 2000-09-08 2002-03-22 Amgen Inc G-csf analog compositions and methods
AU3070702A (en) * 2000-11-07 2002-05-21 Chiron Corp Stabilized inteferon compositions
ATE399794T1 (de) 2001-02-06 2008-07-15 Merck Patent Gmbh Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
US7189830B2 (en) 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
DE60236522D1 (de) 2001-07-11 2010-07-08 Maxygen Inc G-csf konjugate
EP1432822B1 (en) * 2001-09-10 2007-05-23 EMD Biosciences, Inc. Method for recovering and analyzing a cellular component of cultured cells without having to harvest the cells first
US20040247562A1 (en) 2001-09-28 2004-12-09 Sang Yup Lee Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3
ES2516041T3 (es) 2001-10-10 2014-10-30 Ratiopharm Gmbh Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH)
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
SI21273A (sl) * 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
AU2003267827A1 (en) 2002-08-31 2004-03-19 Cj Corp. Glycosylated human granulocyte colony-stimulating factor (g-csf) isoform
US9453251B2 (en) * 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US8399217B2 (en) * 2003-03-14 2013-03-19 Brookhaven Science Associates, Llc High density growth of T7 expression strains with auto-induction option
KR101237651B1 (ko) * 2003-11-19 2013-02-27 다우 글로벌 테크놀로지스 엘엘씨 개선된 단백질 발현 시스템
EP2314602A1 (en) * 2003-11-21 2011-04-27 Pfenex, Inc. Improved expression systems with SEC-system secretion
KR100524872B1 (ko) * 2003-12-04 2005-11-01 씨제이 주식회사 인터페론 베타의 정제방법
AU2005206951B2 (en) 2004-01-16 2010-08-19 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
AU2005269527B2 (en) * 2004-07-26 2011-12-01 Pfenex Inc. Process for improved protein expression by strain engineering
CA2591235C (en) * 2004-12-20 2014-03-11 Cadila Healthcare Limited Process for preparing high levels of interferon beta
EP1828241A1 (en) * 2004-12-23 2007-09-05 Laboratoires Serono S.A. G-csf polypeptides and uses thereof
GB0605684D0 (en) 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
KR20090018799A (ko) * 2006-05-30 2009-02-23 다우 글로벌 테크놀로지스 인크. 코돈 최적화 방법
EP1939212A1 (en) * 2006-12-20 2008-07-02 LEK Pharmaceuticals D.D. Organic compounds
AU2008210538B2 (en) * 2007-01-31 2013-06-06 Pelican Technology Holdings, Inc. Bacterial leader sequences for increased expression
JP5444553B2 (ja) * 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
US9580719B2 (en) * 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
KR20100058541A (ko) * 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
EP2445924B2 (en) 2009-06-25 2023-12-13 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
WO2011109556A2 (en) 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
WO2011123570A2 (en) * 2010-04-01 2011-10-06 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell

Also Published As

Publication number Publication date
US9611499B2 (en) 2017-04-04
ES2639398T3 (es) 2017-10-26
CA2791361A1 (en) 2011-09-09
EP2542574B1 (en) 2017-08-09
PE20130557A1 (es) 2013-05-19
CN102906108B (zh) 2016-01-20
WO2011109556A3 (en) 2012-01-12
CA2791361C (en) 2018-06-12
EP2542574A4 (en) 2014-01-29
KR101857825B1 (ko) 2018-05-14
JP5840148B2 (ja) 2016-01-06
BR112012022292A2 (pt) 2017-01-10
US20160032345A1 (en) 2016-02-04
KR20130018743A (ko) 2013-02-25
CN102906108A (zh) 2013-01-30
CL2012002378A1 (es) 2014-01-10
US20110217784A1 (en) 2011-09-08
AU2011223627A1 (en) 2012-09-27
EP2542574A2 (en) 2013-01-09
RU2573909C2 (ru) 2016-01-27
RU2012141653A (ru) 2014-04-10
AU2011223627B2 (en) 2015-06-18
US9187543B2 (en) 2015-11-17
MX2012010148A (es) 2013-01-22
JP2013524775A (ja) 2013-06-20
NZ602255A (en) 2014-04-30
WO2011109556A2 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
CO6592086A2 (es) Metodo para producir proteinas de interferon recombiantes solubles sin desnaturalizacion
WO2019126634A3 (en) Targeted integration of nucleic acids
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
MY195974A (en) Interleukin-21 Muteins and Methods of Treatment
EA201690600A1 (ru) Метаболически оптимизированная клеточная культура
WO2019224025A3 (en) Antagonizing cd73 antibody
EA201190326A8 (ru) Полипептиды гормона роста и способы их получения и применения
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
SG10201809146QA (en) Recombinant host cell engineered to overexpress helper proteins
EA201791761A1 (ru) Композиция на основе олеаноил-пептида и повышение содержания коллагена
WO2011139853A3 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
WO2011153277A3 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
EP3564259A3 (en) Recognition tags for tgase-mediated conjugation
WO2011139801A3 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl trna synthetases
WO2011140132A3 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
WO2011143482A3 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
AR083354A1 (es) Polipeptidos variantes cbh i (celobiohidrolasas i) con reducida inhibicion de producto
NZ590143A (en) Anti-inflammatory proteins and methods of preparation and use thereof
AR087423A1 (es) Celula capaz de fermentar azucares pentosas
WO2016168214A3 (en) Immunogenic fusion proteins for the treatment of cancer
WO2013134129A3 (en) Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins
AR076774A1 (es) INGENIERIA EPIGENETICA POR MEDIO DE UNA MENOR METILACION DEL ARN RIBOSOMAL OCASIONADA POR UNA DISMINUCION DE LA EXPRESION DE LA PROTEINA 5 DE INTERACCIoN CON EL FACTOR DE TERMINACIoN DE TRANSCRIPCION 1 (TIP-5)
CL2019003459A1 (es) Métodos de cultivo celular.
AR069958A1 (es) Metodo para producir una proteina heterologa de interes